Ergosterol Peroxide Derivatives and Probes for Selective TNBC Targeting
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for triple negative breast cancer (TNBC) lack effective biological targets and mechanisms of action, with existing therapies often leading to increased toxic effects and limited understanding of how ergosterol peroxide (EP) induces cancer cell death.
Innovation Solution
The synthesis of improved derivatives of ergosterol peroxide, such as ergosterol sulfonamide, and the development of fluorescent probes to identify specific biological targets within cancer cells, including Rab interacting lysosomal protein like 1 (RIPL1) and E3 ubiquitin-protein ligase (UBR4), to enhance solubility and cellular accumulation, thereby inducing ROS and apoptosis.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional pharmaceutical therapies are used to treat cancer, then cancer cells are killed, but toxic effects increase
Solution Approach 1:
The patent modifies the chemical structure of ergosterol peroxide by introducing sulfonamide groups at specific positions (C3, C17) to create derivatives with improved therapeutic indices. These structural parameter changes enhance selectivity for cancer cells while reducing toxicity to normal cells, directly addressing the contradiction between efficacy and harmful effects
Solution Approach 2:
The patent introduces functional groups (sulfonamide, fluorescent tags) at specific locations on the ergosterol peroxide molecule to create localized improvements in selectivity and detectability. The sulfonamide groups at C3/C17 positions provide targeted interaction with cancer cell components, while fluorescent tags enable selective visualization without affecting the core anticancer mechanism
2Reliability
If ergosterol peroxide is used to induce apoptosis in cancer cells, then cancer cell death is achieved, but the specific biological targets remain unknown
Solution Approach 1:
The patent employs fluorescent probes as intermediary tools to visualize and track ergosterol peroxide and its derivatives within cancer cells. These probes act as mediators that allow researchers to observe the localization, accumulation, and interaction of the compounds with cellular components, thereby revealing the previously unknown biological targets and mechanisms of action
Solution Approach 2:
The patent incorporates fluorescent tags that emit specific colors when bound to or near biological targets. This color-based detection method enables the identification of specific cellular locations and molecular interactions, transforming the invisible mechanism of action into observable visual data that reveals the biological targets
3Reliability
If derivatives of ergosterol peroxide are synthesized to improve potency, then therapeutic index increases, but solubility and cellular accumulation must be optimized
Solution Approach 1:
The patent systematically modifies physicochemical parameters of ergosterol peroxide derivatives, including the addition of sulfonamide groups and fluorescent tags, to optimize the balance between potency, solubility, and cellular accumulation. These parameter changes enable the compounds to maintain high therapeutic indices while achieving adequate solubility and intracellular delivery
Solution Approach 2:
The patent creates composite molecular structures by combining the ergosterol peroxide core with sulfonamide functional groups and fluorescent tag molecules. This composite approach allows each component to contribute specific properties: the core provides anticancer activity, the sulfonamide groups enhance solubility and selectivity, and the fluorescent tags enable tracking and targeting
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
These derivatives demonstrate superior potency against TNBC cells with a therapeutic index greater than 10, selectively targeting cancer cells without affecting normal cells, and provide insights into the mechanism of action through subcellular localization studies.
Implementation Method 1
EP induces reactive oxygen species (ROS), which are radicals, with a sole unpaired electron in the outermost shell of electrons
Implementation Method 2
the development of fluorescent probes to identify specific biological targets within cancer cells
Implementation Method 3
It is hypothesized that homolytic cleavage of the peroxide would take place to generate the expected oxyl radicals, which ultimately leads to the more stable carbon-carbon radical that would presumably bind to specific proteins
Data Source
AI summary
The bioactive compounds of Ganoderma lucidum extract (GLE) responsible for anticancer activity were elucidated using NMR, X-ray crystallography and analogue derivatization, as well as anti-cancer activity studies. Structures of the seven most abundant GLE compounds are disclosed. Their selective efficacy against triple negative (TNBC) and inflammatory breast cancers (IBC) and other human cancer cell types (solid and blood malignancies) was shown, confirming potential their as anticancer agents.